{"data":{"ticker":"PEN","slug":"penumbra","name":"Penumbra","exchange":"NYSE","sector":"Healthcare","headquarters":"Alameda, California","ceo":"Adam Elsesser","employees":4700,"website":"https://www.penumbrainc.com","founded":"2004","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"},{"slug":"robotics","name":"Robotics & Automation"}],"exposure":{"score":12,"tier":"Peripheral","rationale":"Penumbra sells thrombectomy devices for stroke and clot removal, with AI in imaging analysis and an emerging robotics program. Revenue depends on procedure volumes and device adoption, so AI and robotics are supporting features, not the thesis."},"quote":{"price":319.21,"change24hPct":-0.59,"change7dPct":0.08,"change30dPct":0.53,"change1yPct":19.92,"high52w":359.4,"low52w":266.19,"marketCap":12581465088,"peRatio":80.41,"eps":3.97,"volume24h":107284565},"nextEarningsDate":"2026-11-04","summary":"Penumbra is a medical device company focused on removing blood clots. Its thrombectomy systems treat stroke and other clot conditions, and it earns revenue from hospitals buying devices and the consumables used in each procedure.","explainer":["Penumbra is a medical device company focused on removing blood clots. Its thrombectomy systems treat stroke and other clot conditions, and it earns revenue from hospitals buying devices and the consumables used in each procedure.","AI and robotics are its forward edge. Lightning AI Aspiration adjusts clot removal in real time, AI Stroke Imaging helps identify candidates for intervention, Intelligent Thrombectomy guides procedures, and the REAL Robotics AI program points toward robot-assisted neurovascular care.","Founded in 2004 and headquartered in Alameda, California, Penumbra trades on the NYSE and employs about 4,700 people under CEO Adam Elsesser."],"buildoutRole":"Penumbra sits in the AI Healthcare and Robotics & Automation layers, applying AI at the point of care rather than supplying the buildout. Its algorithms tune clot aspiration and read stroke imaging, and its robotics program extends that into procedure assistance. Revenue depends on procedure volumes and device adoption in hospitals, so AI and robotics support the products instead of driving the thesis. Supercycle scores its AI exposure at 12 out of 100.","faq":[{"q":"What does Penumbra do?","a":"Penumbra makes medical devices for removing blood clots, focused on stroke and neurovascular care. Hospitals buy its thrombectomy systems and per-procedure consumables, which is where the company earns its revenue."},{"q":"How is Penumbra exposed to AI?","a":"Modestly. AI appears in its imaging analysis, its Lightning aspiration technology, and an emerging robotics program, but revenue depends on procedure volumes and device adoption. Supercycle rates its AI Exposure Score at 12 out of 100."},{"q":"What are Penumbra's main AI products?","a":"Lightning AI Aspiration for real-time clot removal control, AI Stroke Imaging for identifying intervention candidates, Intelligent Thrombectomy for procedure guidance, and the REAL Robotics AI program for robot-assisted care."},{"q":"Is PEN a pure play AI stock?","a":"No. Penumbra is a medical device company where AI and robotics are supporting features in its clot removal systems. Its AI Exposure Score of 12 out of 100 reflects that peripheral position."},{"q":"Where is Penumbra based and who leads it?","a":"Penumbra is headquartered in Alameda, California, and led by CEO Adam Elsesser. Founded in 2004, the company employs about 4,700 people and its shares trade on the NYSE."}],"history1y":[{"date":"2026-09-28","close":319.18},{"date":"2026-09-29","close":318.86},{"date":"2026-09-30","close":318.34},{"date":"2026-10-01","close":318},{"date":"2026-10-02","close":317.55},{"date":"2026-10-05","close":317.11},{"date":"2026-10-06","close":317.05},{"date":"2026-10-07","close":316.35},{"date":"2026-10-08","close":317.52},{"date":"2026-10-09","close":319.4},{"date":"2026-10-12","close":320.96},{"date":"2026-10-13","close":320.01},{"date":"2026-10-14","close":320.12},{"date":"2026-10-15","close":321.2},{"date":"2026-10-16","close":320.86},{"date":"2026-10-19","close":322.41},{"date":"2026-10-20","close":324.34},{"date":"2026-10-21","close":323.56},{"date":"2026-10-22","close":324.96},{"date":"2026-10-23","close":324.39},{"date":"2026-10-26","close":325.22},{"date":"2026-10-27","close":324.04},{"date":"2026-10-28","close":318.31},{"date":"2026-10-29","close":321.97},{"date":"2026-10-30","close":318.95},{"date":"2026-11-02","close":321.34},{"date":"2026-11-03","close":320.02},{"date":"2026-11-04","close":322.45},{"date":"2026-11-05","close":321.11},{"date":"2026-11-06","close":319.21}],"incomeStatements":[{"ticker":"PEN","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":1403665000,"cost_of_revenue":461228000,"gross_profit":942437000,"operating_expense":0,"operating_income":189249000,"net_income":177687000,"earnings_per_share":4.52,"earnings_per_share_diluted":4.52,"research_and_development":89766000,"selling_general_and_administrative_expenses":663422000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"PEN","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":1194615000,"cost_of_revenue":439620000,"gross_profit":754995000,"operating_expense":0,"operating_income":86224000,"net_income":14012000,"earnings_per_share":0.36,"earnings_per_share_diluted":0.36,"research_and_development":94783000,"selling_general_and_administrative_expenses":573988000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"PEN","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":1058522000,"cost_of_revenue":375879000,"gross_profit":682643000,"operating_expense":0,"operating_income":91766000,"net_income":90954000,"earnings_per_share":2.32,"earnings_per_share_diluted":2.32,"research_and_development":84423000,"selling_general_and_administrative_expenses":506454000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"PEN","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":847133000,"cost_of_revenue":311926000,"gross_profit":535207000,"operating_expense":0,"operating_income":6082000,"net_income":-2002000,"earnings_per_share":-0.05,"earnings_per_share_diluted":-0.05,"research_and_development":79407000,"selling_general_and_administrative_expenses":449718000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"PEN","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":1826519000,"current_assets":1216684000,"cash_and_equivalents":186897000,"total_liabilities":398916000,"current_liabilities":183133000,"total_debt":219699000,"shareholders_equity":1427603000,"retained_earnings":237691000},{"ticker":"PEN","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":1533181000,"current_assets":951125000,"cash_and_equivalents":324404000,"total_liabilities":382250000,"current_liabilities":158345000,"total_debt":223389000,"shareholders_equity":1150931000,"retained_earnings":60004000},{"ticker":"PEN","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":1556305000,"current_assets":915402000,"cash_and_equivalents":167486000,"total_liabilities":377361000,"current_liabilities":151144000,"total_debt":234343000,"shareholders_equity":1178944000,"retained_earnings":134858000},{"ticker":"PEN","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":1370886000,"current_assets":755699000,"cash_and_equivalents":69858000,"total_liabilities":372028000,"current_liabilities":144932000,"total_debt":235773000,"shareholders_equity":998858000,"retained_earnings":43904000}],"holders13f":[{"slug":"ray-dalio","personName":"Ray Dalio","fundName":"Bridgewater Associates","value":498885,"portfolioPct":0.000020466164631718675,"change":"trimmed","period":"2026-06-30"}],"news":[{"title":"Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/penumbra-pen-stock-faces-q3-141345790.html?.tsrc=rss","date":"2026-10-31"},{"title":"Penumbra: Q3 Earnings Snapshot","source":null,"url":"https://finance.yahoo.com/healthcare/articles/penumbra-q3-earnings-snapshot-202733334.html?.tsrc=rss","date":"2026-10-29"},{"title":"Penumbra, Inc. Reports Third Quarter 2026 Financial Results","source":null,"url":"https://finance.yahoo.com/healthcare/articles/penumbra-inc-reports-third-quarter-200500419.html?.tsrc=rss","date":"2026-10-29"},{"title":"Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)","source":null,"url":"https://finance.yahoo.com/healthcare/articles/penumbras-cavt-technology-receives-fda-130000245.html?.tsrc=rss","date":"2026-10-20"},{"title":"Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus","source":null,"url":"https://finance.yahoo.com/healthcare/articles/penumbra-pen-clinical-data-puts-162002951.html?.tsrc=rss","date":"2026-10-08"},{"title":"New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism","source":null,"url":"https://finance.yahoo.com/healthcare/articles/storm-pe-data-demonstrate-correlation-130000525.html?.tsrc=rss","date":"2026-10-06"},{"title":"IART vs. PEN: Which Stock Is the Better Value Option?","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/iart-vs-pen-stock-better-144002546.html?.tsrc=rss","date":"2026-10-01"},{"title":"IART or PEN: Which Is the Better Value Stock Right Now?","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/iart-pen-better-value-stock-144002774.html?.tsrc=rss","date":"2026-09-29"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.600Z","tier":"free","source":"https://supercyclehq.com/stock/penumbra","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/PEN","html":"https://supercyclehq.com/stock/penumbra","md":"https://supercyclehq.com/stock/penumbra.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}